Read More Pharma Industry News uniQure’s epilepsy data could test whether its gene therapy platform can expand beyond Huntington’s disease Find out how uniQure’s AMT-260 epilepsy data could shape QURE stock sentiment and its broader neurology gene therapy strategy. bySoujanya RaviJune 21, 2026